Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 20/20 | 1.00 |
| ▸ | EGFR | P00533 | 4/20 | 1.00 |
| ▸ | ERBB2 | P04626 | 4/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2963035 | 1.00 | IGF1R (1.00) | IGF1REGFRERBB2 | |
| SCHEMBL2963037 | 1.00 | IGF1R (1.00) | IGF1REGFRERBB2 | |
| SCHEMBL23761177 | 0.94 | IGF1R (0.89) | IGF1REGFRERBB2 | |
| SCHEMBL2959823 | 0.91 | IGF1R (0.85) | IGF1REGFRERBB2 | |
| SCHEMBL2967857 | 0.91 | IGF1R (1.00) | IGF1REGFRERBB2 | |
| SCHEMBL2967858 | 0.91 | IGF1R (1.00) | IGF1REGFRERBB2 | |
| SCHEMBL2967435 | 0.91 | IGF1R (1.00) | IGF1REGFRERBB2 | |
| SCHEMBL2959816 | 0.91 | IGF1R (0.85) | IGF1REGFRERBB2 | |
| SCHEMBL2967437 | 0.91 | IGF1R (1.00) | IGF1REGFRERBB2 | |
| SCHEMBL2961054 | 0.90 | IGF1R (0.82) | IGF1REGFRERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 118 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4739392-A1 | METHODS OF TREATING ACTIVE AND CHRONIC THYROID EYE DISEASE | Viridian Therapeutics, Inc. (US) | 2026-05-13 | — | — | EP | claimed |
| EP-4593956-A1 | METHODS FOR TREATING INACTIVE OR CHRONIC THYROID EYE DISEASE | Horizon Therapeutics Ireland DAC (IE) | 2025-08-06 | — | — | EP | claimed |
| CN-120051302-A | Methods for treating inactivity or chronic thyroid eye disease | 爱尔兰好利恩治疗有限公司 | 2025-05-27 | — | — | CN | claimed |
| EP-4532551-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF THYROID EYE DISEASE | Horizon Therapeutics Ireland DAC (IE) | 2025-04-09 | — | — | EP | claimed |
| WO-2025014774-A9 | METHODS OF TREATING ACTIVE AND CHRONIC THYROID EYE DISEASE | Viridian Therapeutics, Inc. (US) | 2025-03-06 | — | — | WO | claimed |
| WO-2025014774-A1 | METHODS OF TREATING ACTIVE AND CHRONIC THYROID EYE DISEASE | Viridian Therapeutics, Inc. (US) | 2025-01-16 | — | — | WO | claimed |
| WO-2025007012-A2 | USE OF INHIBITORS OF INSULIN-LIKE GROWTH FACTOR RECEPTOR-1 FOR RHEUMATOID ARTHRITIS | Sling Therapeutics, Inc. (US) | 2025-01-02 | — | — | WO | claimed |
| WO-2025007015-A2 | USE OF INHIBITORS OF INSULIN-LIKE GROWTH FACTOR RECEPTOR-1 FOR MULTIPLE SCLEROSIS | Sling Therapeutics, Inc. (US) | 2025-01-02 | — | — | WO | claimed |
| US-20240279323-A1 | METHODS FOR THE TREATMENT OF SCLERODERMA AND RELATED CONDITIONS | HORIZON THERAPEUTICS IRELAND DAC (IE) | 2024-08-22 | — | — | US | claimed |
| US-20240109970-A1 | METHODS FOR TREATING INACTIVE THYROID EYE DISEASE | HORIZON THERAPEUTICS IRELAND DAC (IE) | 2024-04-04 | — | — | US | claimed |
| WO-2024069236-A1 | METHODS FOR TREATING INACTIVE OR CHRONIC THYROID EYE DISEASE | HORIZON THERAPEUTICS IRELAND DAC (IE) | 2024-04-04 | — | — | WO | claimed |
| US-20240043545-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF THYROID EYE DISEASE | HORIZON THERAPEUTICS IRELAND DAC (IE) | 2024-02-08 | — | — | US | claimed |
| WO-2023227952-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF THYROID EYE DISEASE | HORIZON THERAPEUTICS IRELAND DAC (IE) | 2023-11-30 | — | — | WO | claimed |
| US-20230270851-A1 | METHODS FOR THE TREATMENT OF IDIOPATHIC ORBITAL INFLAMMATION AND RELATED CONDITIONS | HORIZON THERAPEUTICS IRELAND DAC (IE) | 2023-08-31 | — | — | US | claimed |
| EP-4100127-A1 | METHODS FOR THE TREATMENT OF SCLERODERMA AND RELATED CONDITIONS | Horizon Therapeutics Ireland Dac (IE) | 2022-12-14 | — | — | EP | claimed |
| CN-115397518-A | Methods of treating scleroderma and related conditions | 赫瑞森治疗学爱尔兰指定活动公司 | 2022-11-25 | — | — | CN | claimed |
| US-20220356257-A1 | METHODS FOR THE TREATMENT OF THYROID EYE DISEASE | HORIZON THERAPEUTICS IRELAND DAC (IE) | 2022-11-10 | — | — | US | claimed |
| CN-115175701-A | Methods for treating thyroid eye disease | 爱尔兰霍里森治疗公司 | 2022-10-11 | — | — | CN | claimed |
| EP-4021500-A1 | METHODS FOR THE TREATMENT OF THYROID EYE DISEASE | Horizon Therapeutics Ireland Dac (IE) | 2022-07-06 | — | — | EP | claimed |
| WO-2026102277-A1 | COMBINATION THERAPIES COMPRISING IKZF2 DEGRADER COMPOUNDS | Plexium, Inc. (US) | 2026-05-15 | — | — | WO | disclosed |
| EP-4739392-A1 | METHODS OF TREATING ACTIVE AND CHRONIC THYROID EYE DISEASE | Viridian Therapeutics, Inc. (US) | 2026-05-13 | — | — | EP | disclosed |
| EP-4730355-A1 | TYPING SYSTEM AND METHOD FOR HR-POSITIVE/HER2-NEGATIVE BREAST CANCER | Lumitype Medical (Huzhou) Co., Ltd. (CN) | 2026-04-22 | — | — | EP | disclosed |
| EP-3226909-B1 | QUATERNARY AMINE COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF | GENENTECH INC (US) | 2026-04-15 | — | — | EP | disclosed |
| US-12600787-B2 | Methods for the treatment of thyroid eye disease | HORIZON THERAPEUTICS IRELAND DAC (IE) | 2026-04-14 | — | — | US | disclosed |
| US-12570625-B2 | 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | NOVARTIS AG (CH) | 2026-03-10 | — | — | US | disclosed |
| US-20260048008-A1 | ORGANOGELS FOR SUSTAINED DRUG DELIVERY, METHODS OF PREPARATION AND USE THEREOF | OCULAR THERAPEUTIX INC (US) | 2026-02-19 | — | — | US | disclosed |
| EP-4695324-A1 | BIO-ORTHOGONAL HYDROGELS FOR SUSTAINED RELEASE DRUG DELIVERY | Ocular Therapeutix, Inc. (US) | 2026-02-18 | — | — | EP | disclosed |
| US-12479817-B2 | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | NOVARTIS AG (CH) | 2025-11-25 | — | — | US | disclosed |
| US-20250353847-A1 | CRYSTALLINE FORMS OF AN AKRIC3 DEPENDENT KARS INHIBITOR | NOVARTIS AG (CH) | 2025-11-20 | — | — | US | disclosed |
| US-20250289802-A1 | 3-(1-OXO-5-(PIPERIDIN-4-YL)ISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2025-09-18 | — | — | US | disclosed |
| EP-4593956-A1 | METHODS FOR TREATING INACTIVE OR CHRONIC THYROID EYE DISEASE | Horizon Therapeutics Ireland DAC (IE) | 2025-08-06 | — | — | EP | disclosed |
| US-20250205347-A1 | METHODS FOR TREATING INFLAMMATORY CONDITIONS OF THE EYE WITH AN IGF-1R LIGAND CONJUGATED TO A DISEASE-MODIFYING AGENT | LIRUM THERAPEUTICS, INC. | 2025-06-26 | — | — | US | disclosed |
| EP-4568658-A1 | ORGANOGELS FOR SUSTAINED DRUG DELIVERY, METHODS OF PREPARATION AND USE THEREOF | Ocular Therapeutix, Inc. (US) | 2025-06-18 | — | — | EP | disclosed |
| EP-4562010-A1 | CRYSTALLINE FORMS OF AN AKR1C3 DEPENDENT KARS INHIBITOR | Novartis AG (CH) | 2025-06-04 | — | — | EP | disclosed |
| CN-120051302-A | Methods for treating inactivity or chronic thyroid eye disease | 爱尔兰好利恩治疗有限公司 | 2025-05-27 | — | — | CN | disclosed |
| EP-4547283-A1 | METHODS FOR TREATING INFLAMMATORY CONDITIONS OF THE EYE WITH AN IGF-1R LIGAND CONJUGATED TO A DISEASE- MODIFYING AGENT | Lirum Therapeutics, Inc. (US) | 2025-05-07 | — | — | EP | disclosed |
| CN-119947711-A | Organogels for sustained drug delivery, methods of preparation and uses thereof | 视尔普斯眼科公司 | 2025-05-06 | — | — | CN | disclosed |
| EP-4532551-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF THYROID EYE DISEASE | Horizon Therapeutics Ireland DAC (IE) | 2025-04-09 | — | — | EP | disclosed |
| CN-119698303-A | Methods for treating inflammatory conditions of the eye with IGF-1R ligands conjugated to disease modifying agents | 利鲁姆治疗公司 | 2025-03-25 | — | — | CN | disclosed |
| WO-2025014774-A9 | METHODS OF TREATING ACTIVE AND CHRONIC THYROID EYE DISEASE | Viridian Therapeutics, Inc. (US) | 2025-03-06 | — | — | WO | disclosed |
| CN-112261970-B | 3- (5-Hydroxy-1-oxo-isoindolin-2-yl) piperidine-2, 6-dione derivatives and their use in the treatment of IKAROS family zinc finger 2 (IKZF 2) dependent diseases | 诺华股份有限公司 | 2025-02-07 | — | — | CN | disclosed |
| US-20250034264-A1 | REGULATING T CELL IMMUNE RESPONSE THROUGH IGF-I RECEPTOR (IGF-1R) | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2025-01-30 | — | — | US | disclosed |
| CN-116134027-B | Heteroaryl-substituted 3- (1-oxo-isoindolin-2-yl) piperidine-2, 6-dione derivatives and uses thereof | 诺华股份有限公司 | 2025-01-24 | — | — | CN | disclosed |
| WO-2025014774-A1 | METHODS OF TREATING ACTIVE AND CHRONIC THYROID EYE DISEASE | Viridian Therapeutics, Inc. (US) | 2025-01-16 | — | — | WO | disclosed |
| CN-119301125-A | Crystalline forms of AKR1C3 dependent KARS inhibitors | 诺华股份有限公司 | 2025-01-10 | — | — | CN | disclosed |
| CN-119241499-A | 3- (5-Hydroxy-1-oxo-isoindolin-2-yl) piperidine-2, 6-dione derivatives and uses thereof | 诺华股份有限公司 | 2025-01-03 | — | — | CN | disclosed |
| WO-2025007015-A2 | USE OF INHIBITORS OF INSULIN-LIKE GROWTH FACTOR RECEPTOR-1 FOR MULTIPLE SCLEROSIS | Sling Therapeutics, Inc. (US) | 2025-01-02 | — | — | WO | disclosed |
| WO-2025007012-A2 | USE OF INHIBITORS OF INSULIN-LIKE GROWTH FACTOR RECEPTOR-1 FOR RHEUMATOID ARTHRITIS | Sling Therapeutics, Inc. (US) | 2025-01-02 | — | — | WO | disclosed |
| US-12180291-B2 | Anti-CCR7 antibody drug conjugates | NOVARTIS AG (CH) | 2024-12-31 | — | — | US | disclosed |
| CN-112334194-B | 3- (5-Amino-1-oxo-isoindolin-2-yl) piperidine-2, 6-dione derivatives and their use in the treatment of I KAROS family zinc finger 2 (IKZF 2) dependent diseases | 诺华股份有限公司 | 2024-12-06 | — | — | CN | disclosed |
| CN-113490528-B | 3- (1-Oxo-5- (piperidin-4-yl) isoindolin-2-yl) piperidine-2, 6-dione derivatives and uses thereof | 诺华股份有限公司 | 2024-12-03 | — | — | CN | disclosed |
| CN-118994402-A | Antibodies to PMEL17 and conjugates thereof | 诺华股份有限公司 | 2024-11-22 | — | — | CN | disclosed |
| WO-2024235337-A1 | TYPING SYSTEM AND METHOD FOR HR-POSITIVE/HER2-NEGATIVE BREAST CANCER | 复旦大学附属肿瘤医院 | 2024-11-21 | — | — | WO | disclosed |
| CN-118955718-A | Antibody drug conjugates and methods of making the same | 诺华股份有限公司 | 2024-11-15 | — | — | CN | disclosed |
| WO-2024215661-A1 | BIO-ORTHOGONAL HYDROGELS FOR SUSTAINED RELEASE DRUG DELIVERY | OCULAR THERAPEUTIX, INC. (US) | 2024-10-17 | — | — | WO | disclosed |
| EP-4427590-A2 | ANTIBODY DRUG CONJUGATES AND METHODS FOR MAKING THEREOF | Novartis AG (CH) | 2024-09-11 | — | — | EP | disclosed |
| CN-113195541-B | Antibodies to PMEL17 and conjugates thereof | 诺华股份有限公司 | 2024-08-30 | — | — | CN | disclosed |
| US-20240279323-A1 | METHODS FOR THE TREATMENT OF SCLERODERMA AND RELATED CONDITIONS | HORIZON THERAPEUTICS IRELAND DAC (IE) | 2024-08-22 | — | — | US | disclosed |
| CN-118420766-A | Antibodies to PMEL17 and conjugates thereof | 诺华股份有限公司 | 2024-08-02 | — | — | CN | disclosed |
| EP-4406555-A2 | ANTIBODIES TO PMEL17 AND CONJUGATES THEREOF | Novartis AG (CH) | 2024-07-31 | — | — | EP | disclosed |
| US-20240245670-A1 | DOSING REGIMEN AND PHARMACEUTICAL COMBINATION COMPRISING 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES | NOVARTIS AG (CH) | 2024-07-25 | — | — | US | disclosed |
| CN-113329792-B | Substituted 3- (1-oxo-isoindolin-2-yl) piperidine-2, 6-dione derivatives and uses thereof | 诺华股份有限公司 | 2024-06-28 | — | — | CN | disclosed |
| US-12006354-B2 | Antibody-IL2 engrafted proteins and methods of use in the treatment of cancer | NOVARTIS AG (CH) | 2024-06-11 | — | — | US | disclosed |
| US-20240158516-A1 | METHODS FOR THE TREATMENT OF THYROID EYE DISEASE | HORIZON THERAPEUTICS IRELAND DAC (IE) | 2024-05-16 | — | — | US | disclosed |
| US-20240141022-A1 | ANTIBODY-CYTOKINS ENGRAFTED PROTEINS AND METHODS OF US IN THE TREATMENT OF CANCER | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC., DBA GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION | 2024-05-02 | — | — | US | disclosed |
| US-20240109970-A1 | METHODS FOR TREATING INACTIVE THYROID EYE DISEASE | HORIZON THERAPEUTICS IRELAND DAC (IE) | 2024-04-04 | — | — | US | disclosed |
| WO-2024069236-A1 | METHODS FOR TREATING INACTIVE OR CHRONIC THYROID EYE DISEASE | HORIZON THERAPEUTICS IRELAND DAC (IE) | 2024-04-04 | — | — | WO | disclosed |
| CN-117813114-A | Methods for treating thyroid eye disorders | 赫瑞森治疗学爱尔兰指定活动公司 | 2024-04-02 | — | — | CN | disclosed |
| EP-3218410-B1 | ANTIBODY DRUG CONJUGATES | NOVARTIS AG (CH) | 2024-03-27 | — | — | EP | disclosed |
| EP-4323526-A1 | ANTIBODY DRUG CONJUGATES AND METHODS FOR MAKING THEREOF | Novartis AG (CH) | 2024-02-21 | — | — | EP | disclosed |
| WO-2024035690-A1 | ORGANOGELS FOR SUSTAINED DRUG DELIVERY, METHODS OF PREPARATION AND USE THEREOF | OCULAR THERAPEUTIX, INC. (US) | 2024-02-15 | — | — | WO | disclosed |
| EP-4320150-A1 | USES OF ANTI-TGF BETA ANTIBODIES AND OTHER THERAPEUTIC AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Novartis AG (CH) | 2024-02-14 | — | — | EP | disclosed |
| US-20240043545-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF THYROID EYE DISEASE | HORIZON THERAPEUTICS IRELAND DAC (IE) | 2024-02-08 | — | — | US | disclosed |
| WO-2024023666-A1 | CRYSTALLINE FORMS OF AN AKR1C3 DEPENDENT KARS INHIBITOR | NOVARTIS AG (CH) | 2024-02-01 | — | — | WO | disclosed |
| EP-4301410-A1 | METHODS FOR THE TREATMENT OF THYROID EYE DISEASE | Horizon Therapeutics Ireland Dac (IE) | 2024-01-10 | — | — | EP | disclosed |
| WO-2024006942-A1 | METHODS FOR TREATING INFLAMMATORY CONDITIONS OF THE EYE WITH AN IGF-1R LIGAND CONJUGATED TO A DISEASE- MODIFYING AGENT | LIRUM THERAPEUTICS, INC. (US) | 2024-01-04 | — | — | WO | disclosed |
| CN-110248963-B | anti-CCR 7 antibody drug conjugates | 诺华股份有限公司 | 2023-12-26 | — | — | CN | disclosed |
| US-11833142-B2 | 3-(5-amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | NOVARTIS AG (CH) | 2023-12-05 | — | — | US | disclosed |
| US-11833215-B2 | CKIT antibody drug conjugates | NOVARTIS AG (CH) | 2023-12-05 | — | — | US | disclosed |
| WO-2023227952-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF THYROID EYE DISEASE | HORIZON THERAPEUTICS IRELAND DAC (IE) | 2023-11-30 | — | — | WO | disclosed |
| CN-117098776-A | Use of anti-TGF-beta antibodies and other therapeutic agents for the treatment of proliferative diseases | 诺华股份有限公司 | 2023-11-21 | — | — | CN | disclosed |
| US-20230321067-A1 | DOSING REGIMEN COMPRISING 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230271940-A1 | HETEROARYL SUBSTITUTED 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2023-08-31 | — | — | US | disclosed |
| US-20230270851-A1 | METHODS FOR THE TREATMENT OF IDIOPATHIC ORBITAL INFLAMMATION AND RELATED CONDITIONS | HORIZON THERAPEUTICS IRELAND DAC (IE) | 2023-08-31 | — | — | US | disclosed |
| US-20230181756-A1 | CCR7 ANTIBODY DRUG CONJUGATES FOR TREATING CANCER | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2023-06-15 | — | — | US | disclosed |
| CN-116134027-A | Heteroaryl-substituted 3- (1-oxo-isoindolin-2-yl) piperidine-2, 6-dione derivatives and uses thereof | 诺华股份有限公司 | 2023-05-16 | — | — | CN | disclosed |
| CN-116096426-A | CCR7 antibody drug conjugates for the treatment of cancer | 诺华股份有限公司 | 2023-05-09 | — | — | CN | disclosed |
| CN-116096862-A | ZBTB32 inhibitors and uses thereof | 诺华股份有限公司 | 2023-05-09 | — | — | CN | disclosed |
| EP-4168007-A1 | DOSING REGIMEN COMPRISING 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES | Novartis AG (CH) | 2023-04-26 | — | — | EP | disclosed |
| US-11634497-B2 | Anti-CCR7 antibody drug conjugates | NOVARTIS AG (CH) | 2023-04-25 | — | — | US | disclosed |
| EP-4165169-A1 | ZBTB32 INHIBITORS AND USES THEREOF | Novartis AG (CH) | 2023-04-19 | — | — | EP | disclosed |
| CN-115916199-A | Dosing regimens comprising 3- (1-oxoisoindolin-2-yl) piperidine-2, 6-dione derivatives | 诺华股份有限公司 | 2023-04-04 | — | — | CN | disclosed |
| EP-4142799-A1 | CCR7 ANTIBODY DRUG CONJUGATES FOR TREATING CANCER | Novartis AG (CH) | 2023-03-08 | — | — | EP | disclosed |
| US-20230067476-A1 | 3-(5-HYDROXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2023-03-02 | — | — | US | disclosed |
| US-20230056470-A1 | USES OF ANTI-TGF-BETA ANTIBODIES AND CHECKPOINT INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2023-02-23 | — | — | US | disclosed |
| US-20230037639-A1 | 3-(5-AMINO-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2023-02-09 | — | — | US | disclosed |
| EP-4100127-A1 | METHODS FOR THE TREATMENT OF SCLERODERMA AND RELATED CONDITIONS | Horizon Therapeutics Ireland Dac (IE) | 2022-12-14 | — | — | EP | disclosed |
| CN-115397518-A | Methods of treating scleroderma and related conditions | 赫瑞森治疗学爱尔兰指定活动公司 | 2022-11-25 | — | — | CN | disclosed |
| US-20220370440-A1 | 4-SUBSTITUTED PYRROLO[2,3-B]PYRIDINE AS ERBB MODULATORS USEFUL FOR TREATING CANCER | LEAD DISCOVERY CENTER GMBH (DE) | 2022-11-24 | — | — | US | disclosed |
| WO-2022243846-A1 | COMBINATION THERAPIES | NOVARTIS AG (CH) | 2022-11-24 | — | — | WO | disclosed |
| EP-3592868-B1 | METHODS OF TREATMENT OF CANCER WITH REDUCED UBB EXPRESSION | NOVARTIS AG (CH) | 2022-11-23 | — | — | EP | disclosed |
| US-20220356257-A1 | METHODS FOR THE TREATMENT OF THYROID EYE DISEASE | HORIZON THERAPEUTICS IRELAND DAC (IE) | 2022-11-10 | — | — | US | disclosed |
| EP-4076660-A1 | USES OF ANTI-TGF-BETA ANTIBODIES AND CHECKPOINT INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Novartis AG (CH) | 2022-10-26 | — | — | EP | disclosed |
| WO-2022221720-A1 | ANTIBODY DRUG CONJUGATES AND METHODS FOR MAKING THEREOF | NOVARTIS AG (CH) | 2022-10-20 | — | — | WO | disclosed |
| WO-2022215011-A1 | USES OF ANTI-TGFβ ANTIBODIES AND OTHER THERAPEUTIC AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2022-10-13 | — | — | WO | disclosed |
| CN-115175701-A | Methods for treating thyroid eye disease | 爱尔兰霍里森治疗公司 | 2022-10-11 | — | — | CN | disclosed |
| US-20220304993-A1 | CONJUGATES OF AN ELECTRON-DONATING NITROGEN OR TERTIARY AMINE COMPRISING COMPOUNDS | ASCENDIS PHARMA A/S (DK) | 2022-09-29 | — | — | US | disclosed |
| CN-115052662-A | Use of anti-TGF-beta antibodies and checkpoint inhibitors for treating proliferative diseases | 诺华股份有限公司 | 2022-09-13 | — | — | CN | disclosed |
| WO-2022187510-A1 | METHODS FOR THE TREATMENT OF THYROID EYE DISEASE | HORIZON THERAPEUTICS IRELAND DAC (IE) | 2022-09-09 | — | — | WO | disclosed |
| US-20220257698-A1 | ANGIOTENSIN TYPE 2 (AT2) RECEPTOR AGONISTS FOR USE IN THE TREATMENT OF CANCER | LANTHIOPEP B.V. (NL) | 2022-08-18 | — | — | US | disclosed |
| EP-3807274-B1 | 4-SUBSTITUTED PYRROLO[2,3-B]PYRIDINE AS ERBB MODULATORS USEFUL FOR TREATING CANCER | LEAD DISCOVERY CENTER GMBH (DE) | 2022-07-27 | — | — | EP | disclosed |
| EP-4021500-A1 | METHODS FOR THE TREATMENT OF THYROID EYE DISEASE | Horizon Therapeutics Ireland Dac (IE) | 2022-07-06 | — | — | EP | disclosed |
| EP-4007592-A1 | ANGIOTENSIN TYPE 2 (AT2) RECEPTOR AGONISTS FOR USE IN THE TREATMENT OF CANCER | LanthioPep B.V. (NL) | 2022-06-08 | — | — | EP | disclosed |
| CN-114514032-A | Angiotensin type 2 (AT2) receptor agonists for the treatment of cancer | 兰提欧派普有限公司 | 2022-05-17 | — | — | CN | disclosed |
| US-20220144807-A1 | 3-(1-OXO-5-(PIPERIDIN-4-YL)ISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2022-05-12 | — | — | US | disclosed |
| US-20220144798-A1 | SUBSTITUTED 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2022-05-12 | — | — | US | disclosed |
| US-11319376-B2 | Combination of glucagon receptor antagonists and PI3K pathway inhibitors for the treatment of cancer | REMD BIOTHERAPEUTICS, INC. (US) | 2022-05-03 | — | — | US | disclosed |
| EP-3986471-A1 | CONJUGATES OF AN ELECTRON-DONATING NITROGEN OR TERTIARY AMINE COMPRISING COMPOUNDS | Ascendis Pharma A/S (DK) | 2022-04-27 | — | — | EP | disclosed |
| EP-3986471-A1 | CONJUGATES OF AN ELECTRON-DONATING NITROGEN OR TERTIARY AMINE COMPRISING COMPOUNDS | Ascendis Pharma A/S (DK) | 2022-04-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (25 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260048008-A1 | ORGANOGELS FOR SUSTAINED DRUG DELIVERY, METHODS OF PREPARATION AND USE THEREOF | KIT, IL33, LY96 | IGF1R 672/4885EGFR 495/4885ERBB2 137/4885 |
| US-20230056470-A1 | USES OF ANTI-TGF-BETA ANTIBODIES AND CHECKPOINT INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | TGFBR1, TGFB1, TGFBR2 | IGF1R 24/4885EGFR 219/4885ERBB2 523/4885 |
| US-20240279323-A1 | METHODS FOR THE TREATMENT OF SCLERODERMA AND RELATED CONDITIONS | IGF1R, IGFBP1, IGFBP2 | IGF1R 1/4885EGFR 163/4885ERBB2 863/4885 |
| US-12479817-B2 | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | XDH, RXFP3, NPY2R | IGF1R 3683/4885EGFR 4330/4885ERBB2 3303/4885 |
| US-20250353847-A1 | CRYSTALLINE FORMS OF AN AKRIC3 DEPENDENT KARS INHIBITOR | AKR1C3, AKR1C1, AKR1C2 | IGF1R 2064/4885EGFR 3998/4885ERBB2 4339/4885 |
| US-12570625-B2 | 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | IKZF1, IKZF2, BCL6 | IGF1R 2521/4885EGFR 2965/4885ERBB2 1680/4885 |
| US-20240245670-A1 | DOSING REGIMEN AND PHARMACEUTICAL COMBINATION COMPRISING 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES | IKZF1, IKZF2, IKZF3 | IGF1R 2388/4885EGFR 2662/4885ERBB2 1780/4885 |
| US-20220144798-A1 | SUBSTITUTED 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | XDH, RXFP3, NPY2R | IGF1R 3683/4885EGFR 4330/4885ERBB2 3303/4885 |
| US-20230270851-A1 | METHODS FOR THE TREATMENT OF IDIOPATHIC ORBITAL INFLAMMATION AND RELATED CONDITIONS | IGF1R, IGFBP1, IRS1 | IGF1R 1/4885EGFR 319/4885ERBB2 548/4885 |
| US-20230037639-A1 | 3-(5-AMINO-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | NPY2R, NPY5R, RXFP1 | IGF1R 3441/4885EGFR 4111/4885ERBB2 3067/4885 |
| US-20230181756-A1 | CCR7 ANTIBODY DRUG CONJUGATES FOR TREATING CANCER | CCR7, BCL6, CXCR3 | IGF1R 1741/4885EGFR 226/4885ERBB2 326/4885 |
| US-20220144807-A1 | 3-(1-OXO-5-(PIPERIDIN-4-YL)ISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | RXFP3, AVPR2, RXFP1 | IGF1R 2151/4885EGFR 4335/4885ERBB2 3186/4885 |
| US-20230271940-A1 | HETEROARYL SUBSTITUTED 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | XDH, SLCO1B3, ROR1 | IGF1R 4145/4885EGFR 4402/4885ERBB2 3155/4885 |
| US-20250289802-A1 | 3-(1-OXO-5-(PIPERIDIN-4-YL)ISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | AVPR2, RXFP3, OPRD1 | IGF1R 2270/4885EGFR 4383/4885ERBB2 3267/4885 |
| US-11833142-B2 | 3-(5-amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | RXFP3, RXFP1, NPY2R | IGF1R 2569/4885EGFR 4101/4885ERBB2 3135/4885 |
| US-20240158516-A1 | METHODS FOR THE TREATMENT OF THYROID EYE DISEASE | TPO, TSHR, TRHDE | IGF1R 916/4885EGFR 1436/4885ERBB2 1449/4885 |
| US-20230321067-A1 | DOSING REGIMEN COMPRISING 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES | IKZF1, IKZF2, IKZF3 | IGF1R 2190/4885EGFR 2645/4885ERBB2 1746/4885 |
| US-20220356257-A1 | METHODS FOR THE TREATMENT OF THYROID EYE DISEASE | TPO, TSHR, TRHDE | IGF1R 916/4885EGFR 1436/4885ERBB2 1449/4885 |
| US-11833215-B2 | CKIT antibody drug conjugates | EPCAM, CD44, CKAP4 | IGF1R 1061/4885EGFR 18/4885ERBB2 17/4885 |
| US-20230067476-A1 | 3-(5-HYDROXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | XDH, HTR1D, RXFP1 | IGF1R 2817/4885EGFR 4482/4885ERBB2 3649/4885 |
| US-12180291-B2 | Anti-CCR7 antibody drug conjugates | CCR7, CXCR3, CXCR4 | IGF1R 1232/4885EGFR 221/4885ERBB2 260/4885 |
| US-20220304993-A1 | CONJUGATES OF AN ELECTRON-DONATING NITROGEN OR TERTIARY AMINE COMPRISING COMPOUNDS | NQO1, HNMT, PNMT | IGF1R 4220/4885EGFR 833/4885ERBB2 802/4885 |
| US-11634497-B2 | Anti-CCR7 antibody drug conjugates | CCR7, CXCR3, CXCR4 | IGF1R 1232/4885EGFR 221/4885ERBB2 260/4885 |
| US-12600787-B2 | Methods for the treatment of thyroid eye disease | TSHR, TRHR, IGF1R | IGF1R 3/4885EGFR 239/4885ERBB2 436/4885 |
| US-20220370440-A1 | 4-SUBSTITUTED PYRROLO[2,3-B]PYRIDINE AS ERBB MODULATORS USEFUL FOR TREATING CANCER | ERBB2, ERBB4, ERBB3 | IGF1R 103/4885EGFR 4/4885ERBB2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.